Neumora Therapeutics is trading at $0.33, down 10.67%, as broader weakness followed hotter-than-expected inflation; no company-specific catalyst was identified for the October 14 decline. - September CPI was 3.7% year over year versus 3.6% expected; core CPI was 2.6% versus 2.5% expected. - Rising Treasury yields and renewed rate-hike concerns pressured growth-sensitive shares broadly. Biotech sector was lower, with XBI down 2.01% during the session; these moves offer context, not proof of a direct company-specific cause.